Additionally, it is necessary to acknowledge that inhibiting one target may activate alternative bypass signaling pathways and potentially allow dormant tumor cells to survive (e.g., via Akt/mTOR), leading to tumor progression and drug resistance[12]. Here, AKT1 is linked to neoplasm.